Engineered extracellular vesicles directed to the spike protein inhibit SARS-CoV-2

SARS-CoV-2 (CoV-2) viral infection results in COVID-19 disease, which has caused significant morbidity and mortality worldwide. A vaccine is crucial to curtail the spread of SARS-CoV-2, while therapeutics will be required to treat ongoing and reemerging infections of SARS-CoV-2 and COVID-19 disease....

Descripción completa

Detalles Bibliográficos
Autores principales: Scott, Tristan A., Supramaniam, Aroon, Idris, Adi, Cardoso, Angelo A., Shrivastava, Surya, Kelly, Gabrielle, Grepo, Nicole A., Soemardy, Citradewi, Ray, Roslyn M., McMillan, Nigel A.J., Morris, Kevin V.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Gene & Cell Therapy 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8806709/
https://www.ncbi.nlm.nih.gov/pubmed/35127966
http://dx.doi.org/10.1016/j.omtm.2022.01.015
Descripción
Sumario:SARS-CoV-2 (CoV-2) viral infection results in COVID-19 disease, which has caused significant morbidity and mortality worldwide. A vaccine is crucial to curtail the spread of SARS-CoV-2, while therapeutics will be required to treat ongoing and reemerging infections of SARS-CoV-2 and COVID-19 disease. There are currently no commercially available effective anti-viral therapies for COVID-19, urging the development of novel modalities. Here, we describe a molecular therapy specifically targeted to neutralize SARS-CoV-2, which consists of extracellular vesicles (EVs) containing a novel fusion tetraspanin protein, CD63, embedded within an anti-CoV-2 nanobody. These anti-CoV-2-enriched EVs bind SARS-CoV-2 spike protein at the receptor-binding domain (RBD) site and can functionally neutralize SARS-CoV-2. This work demonstrates an innovative EV-targeting platform that can be employed to target and inhibit the early stages of SARS-CoV-2 infection.

Ejemplares similares